Health economics最新文献_第3页

Drug Decriminalization and Fatal Traffic Crashes: Evidence From BM110 in Oregon 毒品合法化和致命交通事故：来自俄勒冈州BM110的证据。

IF 2 3区医学

Health economics Pub Date : 2025-01-31 DOI: 10.1002/hec.4944

Christian Gunadi, Yuyan Shi

{"title":"Drug Decriminalization and Fatal Traffic Crashes: Evidence From BM110 in Oregon","authors":"Christian Gunadi, Yuyan Shi","doi":"10.1002/hec.4944","DOIUrl":"10.1002/hec.4944","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <p>Oregon Ballot Measure 110 (BM 110) reduced the penalties for non-commercial possession of a controlled substance, downgrading them from a felony or misdemeanor to a new Class E violation, punishable by a maximum $100 fine. In this paper, we investigate whether BM 110 was associated with changes in drug-related fatal traffic crashes in Oregon after its implementation in February 2021. To do so, we used Fatality Analysis Reporting System (FARS) data from 2018 to 2021 to calculate population-adjusted state-level drug-related fatal traffic crashes. We also employed a modified synthetic control method to create a “synthetic” Oregon, designed to closely resemble the state's pre-policy sociodemographic characteristics and outcome trends while correcting for time-invariant pre-policy differences. The findings show that BM 110 was not associated with changes in drug-related fatal traffic crashes per 100,000 population (0.114, 95% CI: −0.106, 0.334). These results suggest that the implementation of BM 110 did not change drug-related fatal traffic crashes in Oregon in the early period following its adoption.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12847,"journal":{"name":"Health economics","volume":"34 5","pages":"815-820"},"PeriodicalIF":2.0,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143065168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Effects of Resigning GPs on Patient Healthcare Utilization and Some Implications for Health 全科医生离职对病人医疗保健利用的影响及其对健康的启示。

IF 2 3区医学

Health economics Pub Date : 2025-01-30 DOI: 10.1002/hec.4941

Daniel Monsees, Matthias Westphal

引用次数: 0

The Hidden Value of Adult Informal Care in Europe 欧洲成人非正式护理的潜在价值。

IF 2 3区医学

Health economics Pub Date : 2025-01-29 DOI: 10.1002/hec.4928

Joan Costa-Font, Cristina Vilaplana-Prieto

{"title":"The Hidden Value of Adult Informal Care in Europe","authors":"Joan Costa-Font, Cristina Vilaplana-Prieto","doi":"10.1002/hec.4928","DOIUrl":"10.1002/hec.4928","url":null,"abstract":"<p>The hidden value of adult informal care (IC) refers to the unaccounted value of informal care in overall costs of long-term care (LTC) estimates. This paper estimates the net value of adult IC in Europe, drawing on a well-being-based methodology. We use an instrumental variable strategy and a longitudinal and cross-country dataset to estimate the causal effect of the extensive and intensive margin of caregiving on subjective well-being. We estimate the so-called compensating surplus (CS), namely the income equivalent transfer, to compensate for the net disutility of caregiving. We show that IC reduces average subjective well-being by about 1% compared to the mean (6% among co-residential caregivers). Relative to a country's Gross Domestic Product (GDP), the value of IC ranges between 4.2% in France and 0.85% in Germany. Such relative value declines as the country's share of formal LTC spending increases. These results call for a reconsideration of the existing classifications of LTC regimes. We estimate that the average CS per hour for IC is 9.55€, with a range from 22€ per hour in Switzerland to 5€ per hour in Spain. Additionally, we estimate that the long-term CS (estimated using an individual’s permanent income) tends to be lower than short-term CS (estimated using an individual’s current income).</p>","PeriodicalId":12847,"journal":{"name":"Health economics","volume":"34 4","pages":"791-812"},"PeriodicalIF":2.0,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hec.4928","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143065170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Daylight Saving Time and Automobile Accidents: Evidence From Chile 日光节约时间和汽车事故：来自智利的证据。

IF 2 3区医学

Health economics Pub Date : 2025-01-25 DOI: 10.1002/hec.4936

Roberto Gillmore

引用次数: 0

Health Shock Effects on Diet: More Severe Shock—Stronger Response? 健康冲击对饮食的影响：更严重的冲击-更强的反应？

IF 2 3区医学

Health economics Pub Date : 2025-01-22 DOI: 10.1002/hec.4940

Anna Kristina Edenbrandt, Kim Wadt Skak-Hansen, Sinne Smed

引用次数: 0

Substitution and Complementarity in the Consumption of Alcohol, Cannabis, and Opium 酒精、大麻和鸦片消费的替代和互补。

IF 2 3区医学

Health economics Pub Date : 2025-01-17 DOI: 10.1002/hec.4938

Siddharth Chandra, Gaurav Doshi

引用次数: 0

The Effects of Hydrological Disasters on the Population's Health in the Northeast Region of Brazil 巴西东北地区水文灾害对人口健康的影响

IF 2 3区医学

Health economics Pub Date : 2025-01-17 DOI: 10.1002/hec.4939

Vinícius Halmenschlager, Alexandre Nunes de Almeida, Felipe Garcia Ribeiro, Carolina Silva da Trindade

引用次数: 0

Value-Based Pricing for Drugs With Uncertain Clinical Benefits 临床效益不确定的药品价值定价。

IF 2 3区医学

Health economics Pub Date : 2025-01-14 DOI: 10.1002/hec.4932

Boshen Jiao, Yuli Lily Hsieh, Meng Li, Stéphane Verguet

{"title":"Value-Based Pricing for Drugs With Uncertain Clinical Benefits","authors":"Boshen Jiao, Yuli Lily Hsieh, Meng Li, Stéphane Verguet","doi":"10.1002/hec.4932","DOIUrl":"10.1002/hec.4932","url":null,"abstract":"<div>\u0000 \u0000 <p>Policymakers can use cost-effectiveness analysis to set value-based prices (VBP) for new pharmaceuticals. However, the uncertainty of investigational drug benefits complicates this pricing strategy. Such complexity stems from decision-makers' risk aversion and the potential change in the estimated value with emerging evidence. The recent surge in drugs approved via the Accelerated Approval (AA) pathway in the U.S. has made incorporating uncertainty into VBP crucial. We propose to estimate risk-adjusted VBP (rVBP) for drugs with uncertain benefits via integrating value of information and expected utility theory. Our approach involves two assessment points: an initial assessment with existing evidence; and a reassessment with new evidence that reduces uncertainty. This approach enables decision-makers to set rVBP in the initial assessment such that the expected utility, from the exisiting evidence, aligns with the benchmark uncertainty. We evaluate two benchmarks: one with no uncertainty, and one with a decision-maker's acceptable uncertainty level. We show in a case study of a hypothetical AA drug that rVBP may be lower than traditional VBP, especially under high risk aversion or low acceptable uncertainty. Our methodology adjusts VBP to account for uncertainty, supporting decision-makers in balancing timely market access with the risks associated with uncertainty in the benefits of new pharmaceuticals.</p>\u0000 </div>","PeriodicalId":12847,"journal":{"name":"Health economics","volume":"34 4","pages":"780-790"},"PeriodicalIF":2.0,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142983246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessing Cigarette Reduction Tax-Effectiveness in Low Tobacco Expenditure Contexts: An Application to Bolivia 在低烟草支出背景下评估卷烟减免税效果：玻利维亚的应用。

IF 2 3区医学

Health economics Pub Date : 2025-01-14 DOI: 10.1002/hec.4931

Joaquín Morales, Sara Santander

{"title":"Assessing Cigarette Reduction Tax-Effectiveness in Low Tobacco Expenditure Contexts: An Application to Bolivia","authors":"Joaquín Morales, Sara Santander","doi":"10.1002/hec.4931","DOIUrl":"10.1002/hec.4931","url":null,"abstract":"<div>\u0000 \u0000 <p>In this research we show that ambitious increases in tobacco tax rates can substantially reduce tobacco consumption, increase fiscal revenue, and provide net positive social benefits even in contexts of low consumption prevalence and intensity. Low nicotine intake still constitutes a grave disease risk factor, and the effectiveness of tax increases might be questioned if income effects are small. We adapt spatial variation of price methodologies to deal with low prevalence and intensity, censored data, and small samples using the Bolivian case as an illustration. We find an average price elasticity of demand of <span></span><math>\u0000 <semantics>\u0000 <mrow>\u0000 <mo>−</mo>\u0000 <mn>0.69</mn>\u0000 </mrow>\u0000 <annotation> ${-}0.69$</annotation>\u0000 </semantics></math> to <span></span><math>\u0000 <semantics>\u0000 <mrow>\u0000 <mo>−</mo>\u0000 <mn>0.76</mn>\u0000 </mrow>\u0000 <annotation> ${-}0.76$</annotation>\u0000 </semantics></math>. Using our estimates of elasticities, we develop a simulation to anticipate the effects of a 35% yearly increase of the Bolivian specific excise on tobacco starting in 2025. Our estimates show that by 2030, this reform could reduce the consumption of cigarettes by 52.6%, diminish the prevalence of smoking by 30.6%, and increase fiscal revenue by $123 million over six years. Moreover, we estimate that the abated direct medical costs of reduced consumption net of the deadweight loss associated with a tax increase would generate a net social gain of over $100 million in five years.</p>\u0000 </div>","PeriodicalId":12847,"journal":{"name":"Health economics","volume":"34 4","pages":"758-779"},"PeriodicalIF":2.0,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142983234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fat vs. Sugar: The Case for a Saturated Fat Tax in Italy 脂肪与糖：意大利征收饱和脂肪税的案例。

IF 2 3区医学

Health economics Pub Date : 2025-01-12 DOI: 10.1002/hec.4933

Valeria di Cosmo, Silvia Tiezzi

引用次数: 0